Home ProductsAnti Estrogen Steroids
Buy SARM Steroid Powder from sarmsteroidpowder.com, Steroid Powder, Peptide Supplier, SARMs Powder Manufacturer
Product Details:
Payment & Shipping Terms:
|
| Name: | Raloxifene Hydrochloride,Raloxifene HCL | Shipping: | DHL, UPS, EMS, FEDEX, Post, ECommerce |
|---|---|---|---|
| Storage: | Shading, Confined Preservation | Purity:: | 99%+ USP/BP Grade |
Raw Antiosteoporotic SERMs Hormone Powder Raloxifene Hydrochloride Anti-Estrogen Drugs CAS: 82640-04-8
Raloxifene Hydrochloride/Raloxifene HCL Profile:
Product Name:Raloxifene hydrochloride
CAS: 82640-04-8
MF: C28H28ClNO4S
MW: 510.04
Chemical Properties:off-white or yellow solid
Usage: amino acid, nutrient, A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
Raloxifene Hydrochloride/Raloxifene HCL COA
| Test items | Specification | Test results | |
| Appearance | Yellowish powder | Comply | |
| Identification | Ir | Comply | |
| It meets the requirements of the test for choride | Comply | ||
| Solubility | Soluble in 10% sodium hydroxide solution, slightly soluble in methanol,insoluble in water | Comply | |
| Assay | 98.5%~101.5% | 99.15% | |
| Related substances | Rrt=0.74 impurity | ≤0.20% | Comply |
| Other single impurity | ≤0.10% | 0.07% | |
| Total impurities | ≤0.5% | 0.26% | |
| Loss on drying | ≤0.5% | 0.10% | |
| Residue on ignition | ≤0.1% | Comply | |
| Heavy metals | ≤10ppm | Comply | |
| Storage | Preserve in well-closed containers and protected from light.Store at room temperature. | ||
| Conclusion | Complies with usp32 standard | ||
What is Raloxifene Hydrochloride/Raloxifene HCL?
Raloxifene hydrochlorideis an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.
EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration.
Raloxifene Hydrochloride/Raloxifene HCL Effects
1) May prevent or treat corticosteroid-induced bone loss. American College of Rheumatology states that raloxifene can be offered to select postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e. G., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.
2) Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
3) Reduction in the incidence of invasive breast cancer postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial). Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.
Raloxifene Hydrochloride/Raloxifene HCL Side Effects
Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes. Raloxifene is a teratogenic drug, i. e. can cause developmental abnormalities such as birth defects.
Anti Estrogen Steroids:
| Anti Estrogen Steroids | CAS No. |
| Exemestane | 107868-30-4 |
| Clomifene Citrate (Clomid) | 50-41-9 |
| Letrozole | 112809-51-5 |
| Trilostane | 13647-35-3 |
| Anastrozole | 120511-73-1 |
| Fulvestrant | 129453-61-8 |
| Tamoxifen Citrate | 54965-24-1 |
| Raloxifene Hydrochloride | 82640-04-8 |
| Flutamide | 13311-84-7 |
Anti-estrogen Series
| Tamoxifen Citrate | CAS No.: 563.64 |
| Clomifene Citrate | CAS No.: 50-41-9 |
| Toremifene Citrate | CAS No.: 89778-27-8 |
| Exemestane | CAS No.: 107868-30-4 |
| Anastrozole | CAS No.: 120511-73-1 |
| Letrozole | CAS No.: 112809-51-5 |
| Fulvestrant | CAS No.: 129453-61-8 |
Contact Person: David
